BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
Covington
Harvard Business School
US Department of Justice
Accenture
Daiichi Sankyo
Johnson and Johnson
Boehringer Ingelheim
Dow

Generated: January 20, 2018

DrugPatentWatch Database Preview

Eteplirsen - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for eteplirsen and what is the scope of eteplirsen freedom to operate?

Eteplirsen
is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eteplirsen has one hundred and seventy-seven patent family members in twenty-two countries.

One supplier is listed for this compound.
Summary for eteplirsen
International Patents:177
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 7
Drug Prices:see low prices
DailyMed Link:eteplirsen at DailyMed
Pharmacology for eteplirsen

US Patents and Regulatory Information for eteplirsen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-002 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-002 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-002 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-002 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-002 Sep 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for eteplirsen

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,455,634 Antisense oligonucleotides for inducing exon skipping and methods of use thereof ➤ Subscribe
7,625,873 Antisense antibacterial method and compound ➤ Subscribe
8,030,292 Antisense antiviral compounds and methods for treating a filovirus infection ➤ Subscribe
8,415,313 Antisense oligomers and methods for inducing immune tolerance and immunosuppression ➤ Subscribe
6,784,291 Splice-region antisense composition and method ➤ Subscribe
8,524,676 Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds ➤ Subscribe
8,436,163 Splice-region antisense composition and method ➤ Subscribe
7,943,762 Oligonucleotide analogs having cationic intersubunit linkages ➤ Subscribe
9,447,415 Antisense oligonucleotides for inducing exon skipping and methods of use thereof ➤ Subscribe
8,168,604 Antisense antiviral compounds and methods for treating a filovirus infection ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for eteplirsen

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
McKinsey
Johnson and Johnson
Mallinckrodt
Express Scripts
Daiichi Sankyo
Healthtrust
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot